Welcome to our dedicated page for AVAI BIO SEC filings (Ticker: AVAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avaí Bio, Inc.'s SEC filings document material events for a Nevada issuer that changed its corporate name from Avant Technologies Inc. while retaining the AVAI ticker. The filing record includes Form 8-K disclosures on corporate identity, securities registration status and other public-company matters.
The company's filings also report material definitive agreements tied to cell-based therapy collaborations, including joint venture and license arrangements for Insulinova and Klothonova. Additional 8-K disclosures document the termination of a prior artificial intelligence healthcare technology agreement, providing formal records of AVAI's transition toward biotechnology programs involving genetically modified cells and encapsulation-based therapeutic platforms.
Avai Bio, Inc. entered into a Mutual Termination Agreement with Ainnova Tech Inc. on May 7, 2026, ending their Joint Venture and License Agreement that began in November 2024. The joint venture entity, Ai-Nova Acquisition Corp., will be dissolved and its Nevada corporate filings closed.
Both parties agreed to cancel and release all obligations, rights, and liabilities related to the prior arrangement, with no termination penalties or further financial obligations for either side. Avai Bio and Ainnova plan to pursue their business strategies independently while cooperating in good faith to wind down any remaining joint venture activities.
Avaí Bio, Inc. reported another loss-making quarter with no revenue and a larger deficit. For the three months ended December 31, 2025, the company recorded a net loss of $553,727, bringing the nine‑month loss to $1,494,332.
As of December 31, 2025, Avaí Bio had total assets of $172,912, versus total liabilities of $2,967,398, resulting in a stockholders’ deficit of $2,794,486. Cash and cash equivalents were just $50,402, while accounts payable and various loans and convertible notes made up a heavy current liability load.
The company’s auditors highlight substantial doubt about its ability to continue as a going concern, citing recurring losses and the absence of a stable revenue base. Management plans to rely on additional investment capital while pursuing AI and biotech joint ventures that may require up to tens of millions of dollars in future funding commitments.
AVAI Bio, Inc., formerly Avant Technologies, Inc., reported a corporate name change. On February 3, 2026, the Nevada corporation filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State to change its name to Avaí Bio, Inc. The company’s ticker symbol will remain “AVAI.”
Avaí Bio, Inc. (formerly Avant Technologies Inc.) filed its quarterly report for the period ended September 30, 2025. The company reported $0 revenue and a net loss of $453,016 for the quarter. For the six months, net loss was $940,605 as operating expenses focused on G&A, marketing, and initial R&D.
Liquidity remains tight: cash was $91,995 and total assets were $231,372, against total liabilities of $2,532,131, resulting in a stockholders’ deficit of $2,300,759. Management disclosed substantial doubt about the company’s ability to continue as a going concern. Operating cash use for the six months was $611,890, largely offset by $622,832 from financing activities, including related party loans and promissory notes carrying default interest terms.
The company outlined two joint ventures: with Ainnova Tech Inc. (commitment up to $20,000,000 over 12 months) and with Austrianova (up to $1.5 million over 18 months), each at 50/50 ownership. It terminated a prior equity line and withdrew a related S-1, and is pursuing revised financing structures. Common shares outstanding were 137,829,465 at quarter-end and 138,031,533 as of November 14, 2025.
Avant Technologies Inc. (AVAI) entered a Joint Venture and License Agreement with SGAustria Pte. Ltd. to form Insulinova, Inc. Effective November 1, 2025, the parties will co-own Insulinova on a 50%/50% basis and operate it under a limited liability company agreement.
Austrianova intends to contribute its proprietary cell encapsulation intellectual property, know-how, and related resources. AVAI will contribute all resources and capital required for the first eighteen months, not to exceed $1.5 million USD, in exchange for Insulinova common stock, and will use its best efforts to help arrange additional funding at no cost to Austrianova. The full agreement is attached as Exhibit 10.1.
Avant Technologies Inc. entered into a Joint Venture and License Agreement with SGAustria Pte. Ltd. (Austrianova) to form a new company, Klothonova Inc. Avant will provide all resources and capital needed for Klothonova’s formation and operations for the next 18 months, up to $1.5 million, in exchange for common stock.
Austrianova, a biotech company specializing in cell biology and proprietary cell encapsulation technology, will contribute its intellectual property, know-how, and resources. Ownership of Klothonova will be split 50% to Avant and 50% to Austrianova, and it will be governed under a limited liability company agreement. The full Joint Venture and License Agreement is attached as Exhibit 10.1.
Avant Technologies Inc. entered into a Joint Venture and License Agreement with SGAustria Pte. Ltd. (Austrianova) to form a new company, Klothonova Inc. Avant will provide all resources and capital needed for Klothonova’s formation and operations for the next 18 months, up to $1.5 million, in exchange for common stock.
Austrianova, a biotech company specializing in cell biology and proprietary cell encapsulation technology, will contribute its intellectual property, know-how, and resources. Ownership of Klothonova will be split 50% to Avant and 50% to Austrianova, and it will be governed under a limited liability company agreement. The full Joint Venture and License Agreement is attached as Exhibit 10.1.
Avant Technologies Inc. reported that it has filed an application with FINRA to change its corporate name. The company plans to change its name from Avant Technologies Inc. to Avaí Bio, Inc. to better reflect its current business. The ticker symbol will remain “AVAI” until FINRA declares the corporate action effective and, if applicable, assigns a new trading symbol.
Avant Technologies Inc. reported that it has filed an application with FINRA to change its corporate name. The company plans to change its name from Avant Technologies Inc. to Avaí Bio, Inc. to better reflect its current business. The ticker symbol will remain “AVAI” until FINRA declares the corporate action effective and, if applicable, assigns a new trading symbol.